SCHEMBL25528013

SCHEMBL25528013

COC(=O)[C@H](CC(C)C)NC(=O)OCC1CCC(F)(F)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.47
CNR2 P34972 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CTSK P43235 2/20 0.44
CNR1 P21554 1/20 0.43
TAS1R3 Q7RTX0 2/20 0.40
TAS1R1 Q7RTX1 2/20 0.40
CTSL P07711 1/20 0.40
BIRC2 Q13490 1/20 0.39
USP2 O75604 1/20 0.38
CTSS P25774 1/20 0.38
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
FOLH1 Q04609 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28951151 1.00 POLB (0.47) POLBCNR2SMN1; SMN2CTSKCNR1
SCHEMBL25526555 1.00 POLB (0.47) POLBCNR2SMN1; SMN2CTSKCNR1
SCHEMBL23883244 0.91 CTSK (0.43) CNR2CTSKCTSLCTSSFOLH1
SCHEMBL23883243 0.91 CTSK (0.43) CNR2CTSKCTSLCTSSFOLH1
SCHEMBL30211130 0.88 POLB (0.45) POLBCNR2SMN1; SMN2CTSKCNR1
SCHEMBL24113428 0.83 CTSK (0.48) CTSKCTSLCTSS
SCHEMBL23836198 0.83 NAAA (0.37) CNR2CTSK
SCHEMBL30211056 0.82 POLB (0.48) POLBCNR2SMN1; SMN2TAS1R3TAS1R1
SCHEMBL24020560 0.80 CTSL (0.58) CTSL
SCHEMBL29063162 0.80 CTSL (0.58) CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115667215-B Broad-spectrum antiviral medicine for resisting coronavirus 堪萨斯州立大学研究基金会 2026-05-19 CN disclosed
US-12583820-B2 Broad spectrum antivirals against coronavirus KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) 2026-03-24 US disclosed
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-25 US disclosed
EP-4126816-A1 BROAD SPECTRUM ANTIVIRALS AGAINST CORONAVIRUS Kansas State University Research Foundation (US) 2023-02-08 EP disclosed
CN-115667215-A Broad-spectrum antiviral medicine for resisting coronavirus 堪萨斯州立大学研究基金会 2023-01-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583820-B2 Broad spectrum antivirals against coronavirus SARS1, NSUN2, ZC3HAV1 POLB 216/4885CNR2 1863/4885SMN1; SMN2 2304/4885
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION VIM, ACE, ACE2 POLB 13/4885CNR2 4485/4885SMN1; SMN2 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.